Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-001315-71-ES

Enrollment

110

Registered

2013-06-26

Start date

2013-10-17

Completion date

Unknown

Last updated

2013-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia MedDRA version: 16.0 Level: PT Classification code 10039626 Term: Schizophrenia System Organ Class: 10037175 - Psychiatric disorders

Interventions

Trade Name: ABILIFY Pharmaceutical Form: Tablet INN or Proposed INN: ARIPIPRAZOLE CAS Number: 129722-12-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: .. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 110 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: ..

Design outcomes

Primary

Measure	Time frame
Main Objective: ..;Secondary Objective: not applicable;Primary end point(s): ..;Timepoint(s) of evaluation of this end point: ..	—

Secondary

Measure	Time frame
Secondary end point(s): ..;Timepoint(s) of evaluation of this end point: ..	—

Countries

Spain

Contacts

Public ContactMercedes Zumarraga Ortiz

Mercedes Zumarraga Ortiz

mercedes.zumarragaortiz@osakidetza.net3494400 6519

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026